Irish CRO giant ICON this week made Microsoft its technology partner as the organization advances its plan to increase investment in AI over the next three years. Microsoft’s Copilot and data infrastructure will be implemented enterprise-wide to further scale ICON’s agentic AI platform, Orbis.
The deal is designed to help ICON accelerate study design, streamline operations, enhance patient and site engagement, and strengthen decision-making, according to a release issued earlier this week.
The partnership will allow Microsoft’s Fabric and Azure data services to provide ICON’s Orbis with real-time data at scale, enabling faster quality decisions, ICON said. Additionally, the CRO giant plans to leverage Microsoft’s Copilot and Copilot Chat to automate high-volume, repeatable tasks for employees, allowing them to spend more time on higher-value activities.
ICON also plans to deploy agents embedded within clinical trial workflows to accelerate the development of agentic AI.
"The industry is moving to AI as core infrastructure, and we are determined to be at the forefront of this transition to the next generation of clinical trials,” ICON CEO Barry Balfe said in the release. “Our partnership with Microsoft is an important step in our strategy to lead the CRO industry, providing us with productivity tools and a data foundation to further scale Orbis at speed, enabling our teams to work more intelligently, faster and deliver better outcomes for customers, sites and patients."
The Microsoft announcement preceded a first-quarter earnings call that gave analysts at Evercore ISI a clearer view of the company’s recovery. The company reported continued strong bookings in the first quarter, driven by improving underlying demand. The wins “help to provide additional visibility into improving revenue performance and more importantly into a return to organic revenue growth in 2027,” the analyst note read.
Prior to Balfe taking over in October 2025, ICON had suffered from slowing demand from Big Pharma, which resulted in layoffs. Earlier this year, the company revoked its 2025 financial guidance and launched an internal investigation after becoming aware of possible accounting errors in its prior-year financial statements.
In May, ICON concluded its investigation into its accounting practices and restated its consolidated financial statements for 2023 and 2024. The company’s revenue was overstated by 0.8% in full-year 2023 and by 1.1% in full-year 2024.